General Information
Drug ID
DR00162
Drug Name
Etoposide
Synonyms
(-)-Etoposide; 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside; DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; Demethyl EpipodophyllotoxinEthylidine Glucoside; Demethyl-epiodophyllotoxin ethylidene glucoside; Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; E0675; Epipodophyllotoxin VP-16213; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); Eposide; Eposin; Eposin (TN); Eposin, Vepesid, VP-16, Toposar, Etoposide; Etopol; Etopophos (TN); Etopophos (phosphate salt);Etoposide (VP16); Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Etoposido; Etoposido [INN-Spanish]; Etoposidum; Etoposidum [INN-Latin]; Etosid; Lastet; NK 171; Toposar; Trans-Etoposide; VP 16; VP 16 (pharmaceutical); VP 16-213; VP 16213; VP-16; VP-16 (TN); VP-16-213; VePESID (TN); VePesid; Vepesid J; Vepeside; Zuyeyidal
Drug Type
Small molecular drug
Indication Testicular cancer [ICD11: 2C80] Approved [1]
Kaposi's sarcoma [ICD11: 2B57] Approved [1]
Ewing's sarcoma [ICD11: 2B52] Approved [1]
Lung cancer [ICD11: 2C25] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=36462"></iframe>
3D MOL 2D MOL
Formula
C29H32O13
Canonical SMILES
CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
InChI
InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
InChIKey
VJJPUSNTGOMMGY-MRVIYFEKSA-N
CAS Number
CAS 33419-42-0
Pharmaceutical Properties Molecular Weight 588.562 Topological Polar Surface Area 161
Heavy Atom Count 42 Rotatable Bond Count 5
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 13
XLogP
0.6
PubChem CID
36462
PubChem SID
104019076 , 104234176 , 104324084 , 11110521 , 117664408 , 117682510 , 119525100 , 12013288 , 121363248 , 124349593 , 124659141 , 124757097 , 124800231 , 124893613 , 125163901 , 127298729 , 127298730 , 127298731 , 127298732 , 14886949 , 14935915 , 24278178 , 24769897 , 34677904 , 46386954 , 46500626 , 46505434 , 4733 , 47362874 , 48182835 , 48332078 , 49681767 , 49699016 , 49855364 , 53787668 , 56463308 , 57311878 , 597749 , 71825014 , 75974183 , 7847193 , 7979208 , 8145856 , 8174504 , 85148351 , 85788790 , 89850276 , 92308660 , 92308790 , 99437037
ChEBI ID
ChEBI:4911
TTD Drug ID
D0B7EB
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
MRP3 Transporter Info Multidrug resistance-associated protein 3 Substrate [5]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [6]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [7]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [6]
P-GP Transporter Info P-glycoprotein 1 Substrate [8]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MRP2 Transporter Info Km = 617 microM Madin-Darby canine kidney cells (MDCKII)-MRP2 [4]
MRP3 Transporter Info Km = 11.4 microM Spodoptera frugiperda (Sf9) cells-MRP3 [9]
P-GP Transporter Info Km = 461 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [8]
P-GP Transporter Info Km = 255 microM Madin-Darby canine kidney cells (MDCKII)-MDR1 [4]
References
1 Etoposide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
3 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
4 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
5 Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
6 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
7 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
8 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
9 Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.